Psoriasis Clinical Trials in Los Angeles

Showing 101-120 of 160 trials

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

NCT03731052

This Phase 3 study (Study 307) has been designed to determine and compare the efficacy and safety of 188-0551 Spray and Vehicle Spray applied twice daily for up to four weeks in subjects with plaque psoriasis. Subjects will be instructed to apply the test article (188-0551 Spray or Vehicle Spray) to all psoriasis plaques within the designated Treatment Area twice daily for four weeks (Study Day 29), unless the investigator verifies the subject's psoriasis has cleared at Day 15, then test article application will be for 2 weeks (Study Day 15).

Plaque Psoriasis

Therapeutics, Inc.217 participantsStarted Oct 2018

Los Angeles, California, United States • Ocala, Florida, United States • Macon, Georgia, United States +11 more locations

TERMINATEDPhase 3< 1 mile

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

NCT01708603

The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses

Moderate to Severe Plaque Psoriasis

Bausch Health Americas, Inc.1,831 participantsStarted Aug 2012

Birmingham, Alabama, United States • Tucson, Arizona, United States • Hot Springs, Arkansas, United States +150 more locations

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

Psoriasis Trials in Other Cities

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

A Study of Ixekizumab in Participants With Plaque Psoriasis

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

A Study in Participants With Moderate to Severe Psoriasis

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Other Conditions in Los Angeles